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 199 
Summary 200 
 201 
 202 
The aim of this European initiative is to facilitate a structured discussion to improve the next 203 
edition of the International Classification of Sleep Disorders (ICSD), particularly the chapter 204 
on central disorders of hypersomnolence. 205 
The ultimate goal for a sleep disorders classification is to be based on the underlying 206 
neurobiological causes of the disorders with clear implication for treatment or, ideally, 207 
prevention and or healing. The current ICSD classification, published in 2014, inevitably has 208 
important shortcomings, largely reflecting the lack of knowledge about the precise 209 
neurobiological mechanisms underlying the majority of sleep disorders we currently delineate.  210 
Despite a clear rationale for the present structure, there remain important limitations that 211 
make it difficult to apply in routine clinical practice. Moreover, there are indications that the 212 
current structure may even prevent us from gaining relevant new knowledge to better 213 
understand certain sleep disorders and their neurobiological causes. 214 
We suggest the creation of a new consistent, complaint driven, hierarchical classification for 215 
central disorders of hypersomnolence; containing levels of certainty, and giving diagnostic 216 
tests, particularly the MSLT, a weighting based on its specificity and sensitivity in the 217 
diagnostic context.  218 
We propose and define three diagnostic categories (with levels of certainty): 219 
1/ “Narcolepsy” 2/ “Idiopathic hypersomnia”, 3/ “Idiopathic excessive sleepiness” (with 220 
subtypes) 221 
 222 
 223 
 224 
 225 
 226 
 227 
 228 
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 229 
 230 
Introduction 231 
 232 
The goal of a classification 233 
 234 
The ultimate goal for a sleep disorders classification is to be based on the underlying 235 
neurobiological causes of the disorders with clear implication for treatment or, ideally, 236 
prevention and healing. 237 
 238 
Currently, most sleep specialists refer to the International Classification of Sleep Disorders 3rd 239 
edition (ICSD3), published in 2014 to diagnose and classify sleep disorders [1]. This 240 
classification inevitably has important shortcomings, largely reflecting the lack of knowledge 241 
about the precise neurological mechanisms underlying the majority of sleep disorders we 242 
currently delineate.  Despite a clear rationale for the present structure, there remain important 243 
limitations that make it difficult to apply in routine clinical practice. Moreover, the current 244 
structure may prevent us from gaining relevant new knowledge to better understand certain 245 
sleep disorders and their neurobiological causes. 246 
 247 
This “position paper” addresses sleep disorders in adults and discusses shortcomings in the 248 
approach and structure of the ICSD3 in general with subsequent focus on the chapter: 249 
“Central disorders of hypersomnolence”.  By dissecting the inconsistencies and shortcomings 250 
of the current classification, and taking into account recently obtained knowledge, we produce 251 
suggestions for an adjusted and updated section on hypersomnolence. 252 
The aim of our “position paper” is primarily to facilitate discussions in order to: 253 
1. improve a new version of the classification for practical use 254 
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2. define a research agenda in this area, aiming to explore further neurobiological causes 255 
and substrates for sleep-wake complaints and their underlying disorders 256 
 257 
 258 
General comments on the current ICSD3 classification 259 
 260 
Some of our comments on the chapter “Central disorders of hypersomnolence” deal with the 261 
general structure: 262 
- For the classification of some disorders, such as insomnia and restless limb syndrome 263 
(RLS), the diagnosis is based solely on subjective complaints whereas for others, such as 264 
narcolepsy type 1, it presumes a precise pathophysiology. In others such as obstructive sleep 265 
apnea (OSA), diagnosis can be solely defined by findings on ancillary investigations (i.e. 266 
AHI). 267 
- There are no levels or grades of certainty defined for the various diagnoses. 268 
- There are hardly measures of severity for sleep-related symptoms included. 269 
- Several potentially important assessments that can be clinically useful and easy to 270 
apply are not listed as mandatory in confirming or refuting diagnoses, largely due to problems 271 
of reimbursement in many countries including the US. Examples include actigraphy, 272 
hypocretin measurements, and HLA typing. 273 
  274 
Comments on the chapter “Central disorders of hypersomnolence” 275 
 276 
Terminology and consistency 277 
- The chapter is titled “Central disorders of hypersomnolence” but contains a variety of 278 
disorders such as “Insufficient Sleep syndrome” that generally have no “central” cause, but 279 
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are primarily related to behaviour or lifestyle.  In contrast, OSA as one the most prevalent 280 
causes of hypersomnolence is not listed although it may be argued that there is usually no 281 
central origin for OSA. 282 
- It is presumed that introducing the word “Hypersomnolence” in ICSD3, after its 283 
introduction in DSM-5 in 2013 [2],  was intended to solve previous inconsistencies around 284 
other similar terms such as “excessive daytime sleepiness”, “hypersomnia”, and “excessive 285 
sleepiness”. However, it has led to potential further confusion as “hypersomnolence” is used 286 
to describe both the symptom of “excessive sleepiness” and to define a group of disorders: 287 
“Central disorders of hypersomnolence”. This chapter then documents disorders such as 288 
“idiopathic hypersomnia” but not, for example, “idiopathic hypersomnolence” or “Idiopathic 289 
excessive sleepiness”. “Hypersomnolence” as defined in the DSM-5 is very similar to what 290 
used to be the definition of “hypersomnia”. Compared to ICSD3, it covers a larger variety of 291 
possible expressions of daytime sleepiness including an increased need for sleep, but it is 292 
confusing that it is used only to describe expressions of “Hypersomnolence disorders” and is 293 
not meant to be applied to narcolepsy although narcolepsy may have largely overlapping 294 
expressions. 295 
- From their original meanings, excessive daytime sleepiness (EDS) and hypersomnia 296 
are qualitatively different complaints [3-5]. This is not taken into account in ICSD3 and the 297 
distinction is blurred by use of the term “Hypersomnolence”. In this manuscript, we use 298 
“hypersomnolence” as an overarching description for the presence of EDS and/or excessive 299 
need of sleep (ENS) or an increased quantity of sleep (see also the definition section).  300 
- Hypersomnolence is not just characterized by “daily episodes of an irrepressible need 301 
to sleep or daytime lapses into sleep” as in the definition described by ICSD3. The term 302 
usually harbours much more in the way of disabling symptoms. Accordingly, it often includes 303 
impaired vigilance or sustained attention; automatic behaviours; cognitive complaints, 304 
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especially linked to poor memory; and it can be accompanied by increased need for sleep and 305 
severe sleep inertia [6-8].  306 
-  An increased need for sleep as a separable symptom is not defined. There is also no 307 
clarification in distinguishing it from clinophilia: the tendency to remain in bed in a reclined 308 
position without increased actual sleep time when objectively assessed. 309 
- There is no explicit statement about the difference between fatigue and 310 
hypersomnolence. Fatigue may accompany EDS and hypersomnia, but it is a qualitatively 311 
different complaint and never a (core) symptom of a disorder of hypersomnolence, although it 312 
may accentuate the impairment caused by it [9]. 313 
- As mentioned, attentional problems may be an expression of hypersomnolence. 314 
However, there is no guidance as how to separate conditions considered to be “pure” attention 315 
deficit disorders such as attention deficit hyperactivity disorder (ADHD) from complaints of 316 
attention deficit as an expression of a disorder of hypersomnolence [10]. 317 
 318 
Diagnostic criteria and tests 319 
- There are no clear criteria to assess or measure sleep deprivation and circadian rhythm 320 
disturbances as potential causes for hypersomnolence although it is stated that they should be 321 
excluded before making the diagnosis of idiopathic hypersomnia, for example.  322 
- The current classification relies heavily on the MSLT result despite the test having low 323 
sensitivity and specificity for diagnostic purposes [11-13]. Moreover, more recently, the 324 
consistency of the MSLT result over time is suggested to be unreliable for several diagnoses 325 
(see also below) [14-16].  326 
- The ability of the MSLT to quantify sleepiness has only been validated in healthy volunteers 327 
with different degrees of sleep deprivation [17-20]. It is, therefore, questionable whether it is 328 
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justified to base diagnostic categories heavily depending on MSLT results [17] and not taking 329 
age effects into account [21]. 330 
- In clinical practice, it is not uncommon for a single patient to have multiple potential causes 331 
or contributors of hypersomnolence, including sleep deprivation, OSA, and depressed mood 332 
as common examples. It would be helpful to include a paragraph in the classification 333 
regarding this issue. This highlights our lack of knowledge on the difficult question of 334 
whether depression is a primary cause of hypersomnolence in individual patients, especially 335 
given how in many, it fuels symptoms of insomnia [22-24]. 336 
- It is inconsistent that depression may be comorbid in narcolepsy type 1 but must be excluded 337 
in type 2 and idiopathic hypersomnia. 338 
- It is not clear why narcolepsy type 1 should be diagnosed only when the symptoms are 339 
present for at least 3 months when within this period there is clear-cut cataplexy or 340 
established hypocretin deficiency. 341 
 342 
 343 
Relevant new knowledge and remaining unsolved issues  344 
 345 
New knowledge 346 
- It is known for many years that the sensitivity and specificity of MSLT criteria as used in 347 
ICSD3 are acceptable in narcolepsy type 1 and, importantly, appear relatively consistent over 348 
time [14-16, 25]. In contrast, and assessed in more recent studies, the test’s sensitivity, 349 
specificity and particularly consistency over time are much less secure for the currently 350 
defined disorders: narcolepsy type 2, IH and chronic sleep deprivation[14, 25, 26]. 351 
 11 
 
- Recent studies indicate that the sequence of sleep stages as assessed during MSLT testing 352 
may have diagnostic significance [26-28]. REM sleep occurring before stage 2 sleep is 353 
indicative of narcolepsy type 1, for example. 354 
-  It may be diagnostically very helpful to observe video footage of provoked cataplexy 355 
although this approach is clearly labour intensive and only suitable for patients with frequent 356 
cataplexy attacks [29, 30].  357 
-  There are indications that prolonged sleep recordings and observations may offer additional 358 
diagnostic information and improve classification. However, the expense and labour intense 359 
nature of prolonged recording is likely to limit overall acceptance and standardization of 360 
results may be difficult [31].  361 
 362 
Issues to be solved in a new classification of Sleep-Wake disorders 363 
- It remains unclear how chronic sleep deprivation can reliably be assessed or excluded as a 364 
relevant factor. Actigraphy may be helpful but criteria and protocols for assessing the effects 365 
of sleep extension, for example, are lacking.  366 
- It is also unclear how circadian disorders should be reliably assessed or ruled out as causes 367 
for EDS in the absence of precise criteria and diagnostic protocols.   368 
-  As currently defined, it is very likely that the currently defined disorder IH is a 369 
heterogenous entity. It appears sensible to separate a phenotype with an increased need for 370 
sleep from a phenotype without [3-5]. 371 
- It is unclear whether the currently defined disorders IH and narcolepsy type 2 are always 372 
separable entities [32]. Moreover, it is not known if EDS in narcolepsy type 2 can be 373 
distinguished reliably from expressions of chronic sleep deprivation and narcolepsy type 1 [14, 374 
26, 33].  375 
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-  We know that narcolepsy with cataplexy can start as narcolepsy without cataplexy but we 376 
have poorly identified reliable predictors which might include HLA typing (DQB1*06:02). 377 
Currently, only hypocretin deficiency is known to be associated with a risk of subsequent 378 
cataplexy [34].  379 
- Narcolepsy type 1 & 2, and IH are currently largely defined and separated by MSLT criteria. 380 
We know that the result of the MSLT may change over time particularly in narcolepsy type 2 381 
and IH. However, the contributory effects of different levels of sleep deprivation, including 382 
night shifts, in the days and weeks before the individual test is performed are unknown. To 383 
clarify if the MSLT is, indeed, a relatively inadequate test for accurately diagnosing central 384 
disorders of hypersomnolence, we must first establish guidelines how to exclude sleep 385 
deprivation in the week(s) before performing a MSLT. 386 
- Given the current importance of the MSLT in defining whether a subject suffers from IH or 387 
narcolepsy type 2, changes in MSLT results over time will effectively change a diagnosis, 388 
even if the clinical picture is stable. 389 
-  Mindful that the sensitivity and specificity of the MSLT is low for IH and narcolepsy type 2, 390 
we should allow a different approach in future classifications for patients who have genuine 391 
complaints of hypersomnolence but fail to have diagnostic MSLT results. 392 
- There is a need for an international standardization for measuring hypocretin levels. 393 
 394 
In order to solve most of the issues raised, a new consistent, complaint driven, hierarchical 395 
classification, containing levels of certainty, and giving diagnostic tests, particularly the 396 
MSLT, a weighting based on its specificity and sensitivity in the diagnostic context is 397 
proposed.  398 
 399 
 400 
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 401 
Methods 402 
 403 
A European Task Force to develop an updated guideline for the treatment of narcolepsy, 404 
endorsed by the European Neurological Association (EAN), the European Sleep Research 405 
Society (ESRS) and the European Narcolepsy Network (EU-NN), was established in 2017. 406 
Besides primary discussions concerning treatment and management of narcolepsy, issues 407 
were raised concerning diagnostic uncertainties when applying the ICSD3 during initial 408 
meetings in Lugano (2017), Montpellier (2018), Boston (2018), and Bern (2019). The current 409 
paper summarizes these discussions and conclusions. Regarding the provided definitions and 410 
recommendations: they are all ultimately based on consensus and expert opinion, but for all 411 
PubMed searches (period 1979 – April 2019) have been performed first (by GJL, CB and YD), 412 
using the respective appropriate searching terms. “Excessive sleepiness”, “Daytime 413 
sleepiness”, “Hypersomnolence”, “Hypersomnia”, “Cataplexy”, “Narcolepsy AND diagnostic 414 
criteria”, Idiopathic hypersomnia AND diagnostic criteria”, “Multiple Sleep Latency Test”, 415 
“Sustained attention AND sleep ”, “Fatigue”, “Automatic behaviour”, “Clinophilia”, “Sleep 416 
inertia”, Sleep drunkenness”, “Sleep attack”, “Long sleeper”, “Hypocretin”, ”Orexin”, “HLA 417 
narcolepsy”, “Narcolepsy biomarkers”, If recommendations are solely based on expert 418 
opinion it is explicitly stated in the text. The three main authors (GJL, CB, YD) prepared a 419 
first, second and third draft which were then sent for review and revised by the task force. 420 
Consensus on all statements could be reached. 421 
 422 
The approach 423 
There is a focus on: 424 
 14 
 
- Expressions of hypersomnolence as a specific symptom, and on cataplexy as specific marker 425 
for the only central disorder of hypersomnolence with an established cause, namely, 426 
hypocretin deficient narcolepsy.  427 
- Other symptoms such as hypnagogic hallucinations and sleep paralysis are not considered in 428 
depth given their low diagnostic specificity for any particular cause of hypersomnolence. 429 
- Adults. 430 
 431 
Principles: 432 
- First: we provide full definitions for the various concepts discussed. 433 
- Second: the primary complaint of the patient is the starting point of any diagnostic 434 
process. 435 
- Third: the potential multiple dimensions of the complaint of hypersomnolence are 436 
taken into account. 437 
- Fourth: severity of complaints and degrees of certainty of a particular diagnosis are 438 
taken into account. 439 
- Fifth: relevant new knowledge obtained after the publication of the ICSD3 in 2014 is 440 
taken into account, particularly regarding MSLT data 441 
- Sixth: with the exception of narcolepsy type 1, we advocate a hierarchical approach to 442 
the diagnostic process by first excluding sleep deprivation, then sleep apnea and 443 
subsequently circadian rhythm disorders before considering a diagnosis of 444 
hypersomnolence 445 
- Seventh: a diagnosis may shift to different levels of certainty or categories over time, 446 
depending on changes in symptoms or the results of additional diagnostic tests. 447 
 448 
 449 
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Definitions (alphabetical) 450 
 451 
Problems of attention : difficulties with sustaining a purposeful focus on stimuli. 452 
 453 
Automatic behaviours: behaviours that are performed without conscious knowledge or full 454 
voluntary control. 455 
 456 
Clinophilia / high levels of bed rest: the tendency to spend prolonged amounts of time 457 
reclined in bed without objective evidence for increased sleep time. 458 
 459 
Excessive daytime sleepiness (EDS)*: the complaint of an inability to stay awake during the 460 
normal wake period of the day.  461 
 462 
Excessive need for sleep (ENS)**: the complaint of a need for an excessive quantity of sleep 463 
over the full 24 hours period. At least 10 hours of sleep are needed over 24 hours of the day 464 
with the nocturnal component providing at least 9 hours. The complaint for increased need for 465 
sleep must be, associated with impairment and distress related primarily to deteriorated 466 
quality of daytime wakefulness, and cannot be (fully) resolved by increasing the amount of 467 
sleep.  468 
 469 
Fatigue: the complaint of physical and/or mental exhaustion with difficulties in initiating or 470 
sustaining voluntary activities that are not significantly improved by increased rest or sleep. 471 
 472 
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Hypersomnia: the objectified complaint of ENS. An objective assessment of an excessive 473 
quantity of sleep:  at least 10 hours of sleep duration over 24 hours of the day with the 474 
nocturnal component providing at least 9 hours of sleep duration. 475 
 476 
Hypersomnolence: the presence of a complaint of EDS and/or ENS.  477 
 478 
Long sleeper***: a person with a constitutional need for more sleep than average, reflected 479 
in a habitual long nocturnal sleep period of up to 12 hours in the absence of daytime 480 
complaints when this amount of sleep is fully achieved.  481 
 482 
Nap: a short period of sleep during the wake period of the day 483 
 484 
Sleep attack: a relatively sudden occurring unintended nap, not preceded by a feeling of 485 
sleepiness. 486 
 487 
Sleep deprivation: a situation in which a person is not achieving a sufficient amount of 488 
nocturnal sleep as determined by their individual constitutional requirements.  489 
 490 
Sleep inertia and drunkenness: the complaint of difficulty in achieving complete 491 
wakefulness at the end of a sleep period, potentially accompanied by confusion, disorientation, 492 
and poor motor coordination or even ataxia. Sleep drunkenness is considered as a severe 493 
manifestation of this phenomenon [8]. 494 
 495 
Unintended nap: an episode of irresistible sleep, which may occur at any time during the 496 
wake period of the day, but most commonly associated with tedious or monotonous activities. 497 
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 498 
 499 
* This is the definition of the core problem. It must be acknowledged that EDS has multiple 500 
dimensions as explained in chapter 1.1.1. 501 
 502 
**The cut-offs of 9 respectively 10 hrs are based on expert opinion. They are supported by 503 
several publications and the DSM-5 and the previous edition of the ICSD [2, 35, 36]. 504 
However, additional knowledge is needed. Large data sets such as the Database of the 505 
European Narcolepsy Network that also includes information on other hypersomnolence 506 
disorders may provide these data in the near future. Machine learning could support 507 
delineation of cut-off scores [37]. 508 
 509 
*** The cut-off score is expert opinion. It is highly unlikely that a completely healthy person 510 
will need more than 12 hrs of nocturnal sleep. 511 
 512 
 513 
 514 
 515 
 516 
 517 
 518 
 519 
 520 
 521 
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 522 
 523 
Results 524 
 525 
The result of applying the first four principles is described below. The clinical phenotyping 526 
results from history taking rather than from the use of questionnaires. 527 
 528 
1)  Hypersomnolence 529 
 530 
Hypersomnolence may present in two forms, EDS and ENS.  531 
 532 
1.1.1 Manifestations of excessive daytime sleepiness (EDS) 533 
 534 
Clinical symptoms/complaints: 535 
1) The presence of a feeling of daytime sleepiness throughout most of the day as 536 
opposed to symptoms of fatigue  537 
2) Inability to stay awake in monotonous situations with unintended napping and 538 
possibly sleep attacks  539 
3) Acquired need for scheduled napping during the day  540 
4) Difficulty with sustained attention and vigilance 541 
5) Automatic behaviours that can be attributed to EDS 542 
 543 
EDS often is accompanied by cognitive difficulties, particularly memory complaints, and 544 
emotional difficulties, including irritability and distractibility. Headache complaints are also 545 
likely to be commoner. 546 
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 547 
Criteria for presence of EDS:  548 
There is a daily or near daily presence of symptom 2 OR there is the daily presence of 549 
symptom 1 and at least one of the other symptoms listed.  550 
 551 
 552 
1.1.2 Manifestations of excessive need for sleep (ENS) in adults 553 
  554 
Clinical symptoms/complaints: 555 
1) An increased need for sleep in normal daily life. The need must comprise at least 556 
10 hours of sleep per 24 hours and/or at least 9 hours of nocturnal sleep* AND 557 
2) The presence of at least one of the listed symptoms of EDS and/or the presence of 558 
sleep inertia/sleep drunkenness, AND 559 
3) Sleep extension will not (fully) eliminate the symptoms/complaints of 2. 560 
 561 
Criteria for presence of ENS: 562 
There is a daily or near daily presence of all three listed symptoms/complaints. 563 
 564 
* The defined cut-offs are based on expert opinion and in line with definition used in DSM-V. 565 
 566 
1.2.1 Severity of EDS  567 
 568 
Subjective assessment   569 
1) For example the score on the Epworth Sleepiness Scale  570 
2) Frequency of voluntary and involuntary naps (per day/per week) 571 
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3) Presence of complications that can be attributed to EDS (cognitive symptoms, lapses, 572 
accidents) 573 
 574 
Of note: the presence of co-morbid fatigue may increase the burden of EDS. 575 
 576 
Objective assessment  577 
1) Mean sleep latency by MSLT <2-5 min; 5-8 min; > 8 min) 578 
2) Results of vigilance test (SART) 579 
 580 
 581 
1.2.2 Severity of ENS  582 
 583 
Subjective assessment  584 
1) Total number of hours sleep needed over 24 hours when given the full opportunity to 585 
sleep as compared to the amount of sleep normally obtained in the pre-symptomatic 586 
period 587 
2) frequency/duration of inertia/sleep drunkenness following a nocturnal sleep period and 588 
a nap 589 
 590 
Objective assessment  591 
1) the amount of sleep per 24 hours as estimated with two weeks of actigraphy/sleep log 592 
and confirmed by a ambulant PSG recording of at least 24 hours allowing ad libitum 593 
sleep, or at least 24 hours clinical PSG recording in standardized conditions also 594 
allowing ad libitum sleep [31].* 595 
 596 
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* This recommendation is expert opinion supported by the referred study. 597 
 598 
2) Cataplexy  599 
 600 
2.1.1 Presence of typical or unambiguous partial cataplexy (history taking*) [38-42] 601 
1. Bilateral loss of muscle tone in face, neck or legs (buckling knees), with or without 602 
involvement of the arms, in the absence of falls or collapse 603 
2. Events triggered by sudden emotions, particularly of a positive nature related to mirth. 604 
Typical situations include laughing out loud or telling an amusing story/joke; making 605 
a witty remark; or pleasant surprise when unexpectedly meeting a familiar 606 
acquaintance. Other situations include weakness induced by orgasm or occasionally 607 
anger. It is most reliably diagnosed if triggers other than laughter can be identified 608 
given the significant number of healthy people who report a degree of generalised 609 
weakness induced by laughter, particularly in the legs [40, 42]. 610 
3. Duration of episodes from about a second up to 1 minute for a single attack, typically 611 
less than 30 seconds. Sequential attacks caused by a persisting precipitant trigger may 612 
have a much longer duration. 613 
4. Preserved level of consciousness 614 
5. Abrupt return of muscle activity after the attack 615 
6. It is very common to have a second attack in the months after an initial episode unless 616 
treatment immediately started 617 
 618 
2.1.2 Presence of typical or unambiguous generalized cataplexy (history taking*) [38-42] 619 
1. Bilateral progressive loss of muscle tone generally starting in the face or neck and 620 
building up over seconds, leading to a fall to the ground with buckling of the legs 621 
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2. Events triggered by sudden emotions, particularly of a positive nature related to mirth. 622 
Typical situations include laughing out loud or telling an amusing story/joke; making 623 
a witty remark; or pleasant surprise when unexpectedly meeting a familiar 624 
acquaintance. Other situations include weakness induced by orgasm or occasionally 625 
anger. It is most reliably diagnosed if triggers other than laughter can be identified 626 
given the significant number of healthy people who report a degree of generalised 627 
weakness induced by laughter, particularly in the legs [40, 42]. 628 
3. Duration of an episode typically lasts several seconds and up to 2 minutes. In 629 
exceptional cases, sequential attacks may have a much longer duration. 630 
4. Preserved level of consciousness  631 
5. Abrupt return of muscle activity after the attack 632 
 633 
 634 
Supportive criteria [40]:   635 
- Quick clinical response to anti-cataplectic drugs, particularly antidepressants such as 636 
clomipramine or venlafaxine 637 
- Muscle tendon areflexia/H-reflex suppression, particularly during generalized 638 
episodes [41-43]. 639 
 640 
Compatible with typical cataplexy (if criteria above are also met) [39, 40]:    641 
- Occasionally spontaneous episodes 642 
- Facial twitching 643 
- Prolonged episodes after discontinuation of anti-cataplectic drugs (except sodium 644 
oxybate) 645 
- Attacks experienced as asymmetrical but not strictly unilateral 646 
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- A generalized attack may occasionally result in a full-blown sleep episode 647 
 648 
* There is debate whether cataplectic attacks always start in the neck and face, and also if 649 
muscle jerking or twitches are part of the typical clinical picture of cataplexy although 650 
observations made by experts lend support to this view. However, since we rely on history 651 
taking and not all patients experience these observations, these elements are not part of the 652 
mandatory criteria. 653 
 654 
2.2 Severity of cataplexy  655 
By history  656 
1) Frequency of cataplexy episodes with ranges typically quantified as less than 1 per 657 
month to more than 5 per day [44] 658 
2) Typical duration of episodes 659 
3) Presence or absence of generalized attacks (e.g. associated with falls) 660 
4) Subjective levels of disability caused by episodes of cataplexy, taking into account the 661 
typical situations in which they occur (e.g. at workplace) 662 
 663 
2.3 Certainty of typical cataplexy 664 
- The optimal method for confirming the presence of cataplexy relies on direct observation by 665 
an experienced clinician in real life or, more typically, from recorded video material [29, 30]. 666 
 667 
- Unfortunately, direct or recorded observations are rare to witness in adult patients and 668 
reliance is placed on accurate history taking. Only descriptions fulfilling all characteristics 669 
above can be considered as typical cataplexy.  670 
 671 
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Cataplexy should still be considered, but as atypical, if the patient reports one of the 672 
following features during history taking: 673 
- attacks are purely unilateral or unusually prolonged in the absence of the precipitant (> 3 674 
min) 675 
- no clear precipitants for episodes or if only negative emotions act as triggers 676 
- it is uncertain whether consciousness is fully preserved  677 
- hyperacute generalised muscle weakness without build-up over seconds, leading to falls and 678 
injuries. 679 
- only generalized attacks 680 
- it takes minutes or longer to recover after a single attack 681 
 682 
-If more than one of the above listed characteristics is present the attacks must be considered 683 
to be “cataplexy-like” attacks. In all such cases, the measurement of hypocretin-1 in CSF 684 
may be helpful, as presence of low hypocretin favours presence of cataplexy and high levels 685 
of hypocretin decreases probability of cataplexy. 686 
 687 
- Cataplexy is generally excluded if there is no doubt that loss of consciousness or awareness 688 
occurs at the onset of episodes. 689 
 690 
 691 
 692 
 693 
 694 
 695 
 696 
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 697 
 698 
 699 
3) Proposal for a new classification of central disorders of hypersomnolence in adults 700 
 701 
 We believe the current ISCD3 guidelines on central causes of hypersomnolence have created 702 
a degree of diagnostic confusion by: 703 
-  not consistently taking the symptomatic complaint of the patient as a starting point 704 
- not emphasising the importance or impact of chronic sleep deprivation in the clinical 705 
assessment of hypersomnolence and its influence on the results of ancillary investigations 706 
- incorporating the detailed results of the MSLT as primary diagnostic criteria for certain 707 
categories of hypersomnolence 708 
 709 
The exaggerated and arguably unjustified central role for MSLT results to influence diagnosis 710 
has over-shadowed the importance and relevance of detailed clinical characteristics in 711 
disorders causing hypersomnolence. Moreover, it has stifled the search for updated and more 712 
accurate diagnostic strategies.  713 
We argue that progress will depend on more descriptive diagnostic categories that permit 714 
changes in MSLT results over time without necessarily producing differing diagnostic labels. 715 
We would also advocate the introduction of “probable” diagnoses when the MSLT result is 716 
intermediate and potentially alternative explanations or diagnoses such as chronic sleep 717 
deprivation, OSA and circadian disorders after these have been adequately addressed. 718 
However, we advocate to avoid the use of “possible” diagnosis to prevent confusion for 719 
patients and health insurance companies (a diagnosis labelled as “possible” might be interpret 720 
to be uncertain or unclear). Finally, it should be acknowledged that problems of sustained 721 
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attention or vigilance may be the most disabling aspects of patients with hypersomnolence, as 722 
opposed to sleepiness per se.  723 
With the previous discussions in mind, we now propose a new classification for disorders of 724 
hypersomnolence that is aimed to improve diagnostic clarity and our understanding of 725 
disorders causing hypersomnolence. Moreover, it will facilitate treatment pathways for those 726 
who suffer from complaints of hypersomnolence in whom MSLT results have not necessarily 727 
fulfilled strict diagnostic criteria and in whom sleep deprivation has been satisfactorily 728 
excluded. 729 
 730 
When OSA, chronic sleep deprivation and circadian rhythm disorders have been effectively 731 
excluded, we suggest the creation of three diagnostic categories, with levels of certainty, for 732 
central disorders of hypersomnolence : 733 
 734 
1 “Narcolepsy” replacing NT1 and NT2 735 
2 “Idiopathic hypersomnia”   736 
3 “Idiopathic excessive sleepiness”  737 
 738 
Only for narcolepsy are there criteria proposed for primary (idiopathic), familial, secondary 739 
(symptomatic), and narcolepsy plus (hereditary forms with additional neurological symptoms) 740 
forms [45]. We suggest discontinuing entities such as “hypersomnia due to medical disorder”, 741 
“hypersomnia due to substance abuse”, or “hypersomnia associated with a psychiatric 742 
disorder”, because in most cases it is generally unknown if the relationship is truly causal or 743 
simply co-morbid [22, 24]. Instead, medical disorders and psychiatric disorders including 744 
substance abuse are considered and listed as possible co-morbidities. This is in line with the 745 
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decision made in ICSD3 to allow to diagnose insomnia independently from the presence of a 746 
mental disorder, a medical condition, or drug or substance intake.  747 
We suggest no changes to the diagnostic criteria for Kleine-Levin syndrome because we focus 748 
on chronic disorders characterized by persistent and not remittent hypersomnolence. 749 
3.1 Diagnostic criteria for narcolepsy 750 
 751 
Level 1  A.  752 
Definite  EDS and or typical cataplexy and CSF hypocretin deficiency* 753 
 754 
B.  755 
EDS with typical cataplexy and MSLT**: SL < 8 min and > 1 SOREM 756 
(including nocturnal sleep) 757 
 758 
Level 2 A.  759 
Probable  EDS with typical cataplexy and MSLT**: either SL < 8 min or > 1 760 
 SOREM (including nocturnal sleep) 761 
  762 
B. 763 
EDS without typical cataplexy, but with HH and or SP and or disturbed 764 
nocturnal sleep; MSLT**: SL < 5 min and > 1 SOREM or SL < 8 min 765 
and > 2 SOREMs (including nocturnal sleep) & HLA DQB1*0602 766 
positive*; other causes of EDS need to be excluded¶.  767 
 768 
    769 
Familial***   - EDS with cataplexy or cataplexy-like episodes****; MSLT*: SL < 8 770 
min and > 1 SOREMP, and or hypocretin deficiency; At least one first 771 
degree family member with similar complaints including cataplexy. 772 
 773 
Symptomatic or  774 
secondary*** - EDS with cataplexy or cataplexy-like episodes****; the subject is 775 
known to suffer from Niemann Pick type C, Prader-Willi syndrome, or 776 
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has a demonstrated lesion in the hypothalamus [45, 46]. MSLT*: SL < 777 
8 min and > 1 SOREMP, or hypocretin deficiency 778 
 779 
 780 
* Hypocretin deficiency is considered both the primary cause and most specific biological 781 
marker for narcolepsy with cataplexy. The presence of hypocretin deficiency in an individual 782 
is key to determining the level of certainty in this diagnostic classification. Category 1A is 783 
therefore the most certain category. When applying the strict interpretation of typical 784 
cataplexy which is mandatory, 98% of the category 1B patients will be hypocretin deficient 785 
(familial en secondary cases excluded, see below). 786 
 787 
Hypocretin-1 measurement in the CSF, by adjusted radio immune assay (RIA), is by far the 788 
most specific and sensitive test to diagnose narcolepsy with (typical) cataplexy [47]. By 789 
definition it is diagnostic for narcolepsy type 1 [1]. For the Stanford group, and those who 790 
adjust to Stanford values by using Stanford reference samples, the cut off is 110 pg/ml. In a 791 
clinical context, a value below this concentration is considered diagnostic. Intermediate 792 
hypocretin-1 levels between 110-200 pg/ml cannot exclude the diagnosis but there are 793 
currently not enough data to alter cut off levels to higher than 110 pg/ml. New methods of 794 
measuring CSF-hypocretin for example by mass spectrometry are under development. 795 
Currently, the mentioned cut-off points cannot be used in ELISA-based methods, which may 796 
show abnormally low values, and hence falsely positive results. 797 
 798 
In non-familial and non-secondary cases of narcolepsy type 1, 98% are HLA DQB1*0602 799 
positive [48]. In narcolepsy type 2, this percentage is much lower, averaging 40 to 50%. 800 
However, in the group of narcolepsy type 2, HLA DQB1*0602 positivity is nearly always 801 
seen if there is subsequent hypocretin deficiency or symptoms of cataplexy [34]. In the 802 
general population, the presence of HLA DQB1*0602 is 15 – 38% [48, 49]. Therefore, the 803 
presence of HLA is not helpful as a primary diagnostic tool but can provide evidence to 804 
exclude it and for predicting eventual hypocretin status.  805 
 806 
Typical cataplexy is the clinical hallmark of narcolepsy type 1. It is therefore very important 807 
to define typical cataplexy as precise as possible. For this reason chapter 2 was added.  808 
 809 
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Additional support for hypocretin deficiency, beyond the presence of (typical) cataplexy:  810 
Subjective symptoms: 811 
- ESS >14 [39, 45, 50] 812 
- frequent daily naps that are typically short, refreshing and associated with dream content [38, 813 
45] 814 
 815 
Objective testing: 816 
Considered to be “proven” support: 817 
- MSLT: mean SL < 5 min [34, 51] 818 
- at least 2 SOREMPs [34] 819 
- sleep stage sequence[27, 52-54] 820 
- Short REM sleep latency nocturnal sleep (< 15 min) [55]. The evidence is strong in one 821 
study but there has never been an independent confirmation and the specificity for narcolepsy 822 
type 1 was very high but much less for hypocretin deficiency. Moreover, the sensitivity of this 823 
finding is low.  824 
- Consistent abnormal MSLT findings when repeating the MSLT   825 
Suggested support but needs better validation: 826 
-  absolute REM sleep latency MSLT < 6 min [27, 37] 827 
- sleep stage sequence (REM sleep before occurrence stage 2 sleep or frequent transition 828 
REM to stage 2) [27, 52, 53] 829 
- Relevant findings on a group level that need replication and validation to be added as 830 
diagnostic criteria are: sleep stage sequence/transitions in nocturnal sleep [53, 56] distribution 831 
of eye movement during sleep stages [57], and power spectra analyses [58, 59]. 832 
 833 
** For an accurate interpretation of the MSLT, age should be taken into account [15, 21] 834 
 835 
*** In familial and secondary cases, both the presence of HLA DQB1*0602, and hypocretin 836 
deficiency in the CSF are less prevalent when compared to the idiopathic cases [60, 61]. 837 
 838 
**** For definition, see 2.3 839 
 840 
¶ Diagnoses to be excluded are chronic sleep deficiency, circadian rhythm disorders and OSA. 841 
It is important to realize that there is a hierarchy. First exclude sleep deprivation as cause of 842 
the complaints. If the complaints disappear after sleep extension, the complaint is cured and 843 
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the diagnostic process is completed. If the complaint remains, circadian rhythm disorders and 844 
OSA need to be excluded or treated when they might be responsible for the complaint. Only 845 
after completing these steps, and a remaining complaint that qualifies for narcolepsy level 2B, 846 
the diagnostic process to assess whether the diagnostic criteria for narcolepsy level 2B are met 847 
can be started. Symptoms must be present daily for at least 3 months, 848 
 849 
Narcolepsy phenotype [45] 850 
- acute  851 
- progressive  852 
- chronic-stable  853 
- chronic unstable  854 
- other  855 
 856 
Narcolepsy aetiology [45] 857 
- idiopathic (sporadic) 858 
- familial 859 
- secondary (symptomatic) 860 
- narcolepsy plus (hereditary forms with additional neurological symptoms)  861 
 862 
Severity of narcolepsy* 863 
To be taken into account  864 
- severity score of EDS (see 2.1.2)  865 
- severity score of cataplexy (see 2.2) 866 
- severity score for disturbance nocturnal sleep including the severity of HH 867 
and or SP 868 
- quality of life score 869 
- score for severity of comorbidity 870 
 871 
* a severity score has been suggested which could be elaborated on [62]. 872 
 873 
Frequent co-morbidities of definite and probable narcolepsy in adults [45] 874 
 875 
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- Sleep disorders/disturbances: sleep disordered breathing, RLS/PLMS, RBD, other 876 
parasomnias 877 
- Medical disorders/disturbances: obesity, diabetes mellitus type 2, autonomic instability and 878 
cardiovascular disorders 879 
- Psychiatric disorders/disturbances: anxiety, depression, psychosocial problems 880 
 881 
3.2 Diagnostic criteria for idiopathic hypersomnia 882 
 883 
By definition, sleep deprivation as primary cause is excluded. Sleep apnea as cause needs to 884 
be excluded and in case of doubt, first be treated. 885 
 886 
Level 1 887 
Definite IH*      888 
 889 
1. The presence of ENS 890 
2. The ENS complaint is acquired** 891 
3. There is objective evidence for increased sleep need using actigraphy and PSG*** 892 
 893 
Level 2 894 
Probable IH* 895 
 896 
1. The presence of ENS 897 
2. The ENS complaint is acquired** 898 
3. There is objective support for increased sleep need using actigraphy and PSG*** 899 
 900 
 901 
   902 
* The complaint must be present daily for at least 3 months and all 3 criteria must be fulfilled.  903 
Fatigue may be present but the excessive need for sleep must be the most prominent 904 
complaint. There should be no concomitant major systemic symptoms or factors such as fever 905 
or severe pain as these may indicate chronic inflammatory conditions, infection, or auto-906 
immune disorders. It is uncommon that the disorder develops in or after middle-age. 907 
Depression may be present and it is often appropriate to document it as a co-morbidity. 908 
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 909 
** The point at which symptoms start or even if the disorder is truly acquired may be difficult 910 
to establish when ENS is reported in (early) childhood [5, 63].  911 
 912 
*** For level 1, the criteria for objective confirmation are (both must be fulfilled): 1. 913 
Actigraphy with sleep logs (2 weeks):  strongly supports > 9 hours sleep per night or > 10 914 
hours sleep over 24 hrs on the majority of days, and 2. PSG recording (performed at end 915 
actigraphy recording); preferably > 19 hrs of sleep in a 32-hrs clinical protocol with 916 
standardized conditions [31], or, alternatively, a clinical or ambulant PSG performed for  32-917 
hrs (night 1 + daytime + night 2) allowing ad libitum sleep showing > 19 hrs of sleep. 918 
For level 2: not fulfilling criteria for level 1, but: 1. Actigraphy with sleep logs (2 weeks): 919 
strongly supports > 9 hours of sleep over 24 hrs on the majority of days, and 2. PSG 920 
(performed at end actigraphy recording): result 32-hrs protocol supports but does not meet the 921 
19 hrs criterium, or a PSG for 32-hrs allowing ad libitum sleep is supportive but the PSG does 922 
not fully meet the 19 hrs criterium or is not performed as requested for level 1. 923 
For both levels sleep efficiency for nocturnal sleep must be > 85% (at least when diagnostics 924 
are applied up to middle ages). If CSF hypocretin-1 measurement is performed, the 925 
hypocretin-1 concentration should be in the normal range. 926 
These criteria are essentially expert opinion although particularly the 32 hours PSG protocol 927 
is supported by a study.  928 
 929 
Severity criteria 930 
See severity criteria of ENS paragraph 1.2.2. An existing and recently published scale might 931 
be useful [64]. 932 
 933 
Comorbidities 934 
- Depression, anxiety, chronic fatigue, circadian disorders, attention disorders are relatively 935 
frequently seen 936 
 937 
 938 
 939 
 940 
 33 
 
 941 
 942 
 943 
 944 
 945 
3.3 Diagnostic criteria for Idiopathic excessive sleepiness   946 
 947 
The diagnosis can only be made after exclusion of sleep apnea, chronic sleep deprivation, and 948 
circadian disorders as likely causes of the sleep-related complaints (see ¶ paragraph 3.1).  949 
If the criteria for narcolepsy or IH are fulfilled, these diagnoses should be made. 950 
 951 
  952 
Level 1                                   1. EDS complaint (as defined earlier)* 953 
Definite*  2. Confirmed by PSG and MSLT: SL < 8 min**  954 
3. Not fulfilling criteria for narcolepsy or IH 955 
  956 
Level 2 957 
Probable*:   1. EDS complaint (as defined earlier)* 958 
2. MSLT: SL > 8 and < 12 min 959 
3. Not fulfilling criteria for narcolepsy or IH 960 
  961 
Subtype 1                               962 
“REM type“   1. ≥1 SOREM on PSG / MSLT  963 
                                                2. Findings on SART may be normal or abnormal 964 
  965 
Subtype 2 966 
“NREM type“   1. No SOREM on PSG / MSLT  967 
2. Normal findings on SART  968 
  969 
Subtype 3              970 
”Attention type“  1. No SOREM on PSG / MSLT  971 
2. Abnormal findings on SART  972 
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  973 
  974 
* The complaint is present for at least three months 975 
 976 
** Those with inconsistent MSLT results over time will qualify for one of these categories, 977 
unless criteria for narcolepsy or IH are met. 978 
 979 
*** The Sustained Attention to Response Task (SART) is a vigilance test to assess sustained 980 
attention.  It has been applied and validated in patients suffering from hypersomnolence, 981 
ADHD and brain injury [7, 65, 66]. For the SART cut off values are defined : for the 982 
instruction “prefer accuracy over speed”, the cut-off is 6 [67]. The Psychomotor Vigilance 983 
Test (PVT) might be a good alternative for the SART but there are no cut-off data validated 984 
for patients with hypersomnolence [68].  985 
 986 
Severity criteria 987 
See severity criteria paragraph 1.2.1  988 
 989 
Comorbidities 990 
- Depression, anxiety, chronic fatigue, attention disorders are frequently seen. 991 
 992 
 993 
 994 
 995 
 996 
 997 
 998 
 999 
 1000 
 1001 
 1002 
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 1003 
 1004 
 1005 
 1006 
Discussion 1007 
 1008 
US clinicians were the first to create a classification of sleep and arousal disorders in 1979 1009 
[69]. In 1990 the first edition of the International Classification of Sleep Disorders (ICSD) 1010 
was published, again with US physicians in the lead but representatives of sleep disorders 1011 
associations outside the US became involved. The same holds true for the current edition of 1012 
the classification, the ICSD3, published in 2014. All subsequent editions provided 1013 
improvements but nevertheless it is not uncommon to be difficult or even impossible to make 1014 
a proper diagnosis, including in people consulting us because of convincing complaints of 1015 
hypersomnolence. In the absence of a proper diagnosis people who might deserve treatment 1016 
may remain untreated. Discussions evoked by these experiences ultimately resulted in this 1017 
position paper. 1018 
Clinicians, researchers, and particularly members of classification committees working in the 1019 
field of hypersomnolence should acknowledge the lack of knowledge and understanding of 1020 
the precise underlying neurobiological cause(s) of hypersomnolence and therefore the 1021 
uncertainty if disorders we currently define are real disease entities. Moreover, the impact of 1022 
lifestyle factors is often poorly characterised or appreciated. In such a situation a tendency to 1023 
compensate the lack of knowledge by overemphasizing the qualities and properties of any 1024 
biological markers we currently have should be resisted. It is our contention that the current 1025 
classification system is unintentionally prone to this tendency. This is not only a problem for 1026 
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patient care but may also prevent us from identifying additional biomarkers for sleep 1027 
disorders. 1028 
We therefore suggest a different approach. Differences between the current and our approach: 1029 
- Our classification is much more complaint driven  1030 
- We emphasize that excessive daytime sleepiness is a multidimensional complaint and 1031 
qualitatively different from an increased need for sleep.  1032 
- We use “hypersomnia” only to describe the presence of objectified ENS. 1033 
- We acknowledge that attentional problems frequently accompany disorders of 1034 
hypersomnolence and isolated attention disorders should be separated from sleep disorders. 1035 
- Sleep deprivation, OSA and circadian disorders need to be initially excluded as primary 1036 
causes of EDS. This allows the differentiation of true central disorders of hypersomnolence 1037 
from disorders related to lifestyle disorders and sleep related breathing disorders. In case of 1038 
doubt the effect of increased time in bed, a therapeutic test with CPAP, or circadian alignment 1039 
must first be established. Guidelines from the National Sleep Foundation may help to identify 1040 
the presence of sleep deprivation [70]. 1041 
- We exclude possible confounders for changes in MSLT results over time. 1042 
- If MSLT results change over time we emphasise this should not necessarily have an 1043 
immediate major impact on diagnostic categories and affect patients’ access to treatments, for 1044 
example. 1045 
- Within our classification, patients can shift to more certain levels of diagnosis over time. 1046 
This will potentially provide more insight in how disorders of hypersomnolence progress or 1047 
develop and will help to guide future research agenda. 1048 
- We allow and formalise a certain level of diagnostic uncertainty, reflecting clinical reality in 1049 
daily medical practice.  1050 
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- There will be relatively few patients who will switch to a new diagnosis as a result of a new 1051 
classification. 1052 
We realize that implementation of our proposal will have much impact on the current 1053 
practices around the world. Different insurance systems and availability of the recommended 1054 
tests (i.e. CSF orexin measurement, HLA typing, actigraphy, long term PSG recording) may 1055 
be an issue for clinicians in some countries. However, our proposal is to move forward the 1056 
field to improve the knowledge and management of patients affected with hypersomnolence. 1057 
The main objectives are 1.to diagnose homogeneous groups of patients affected with these 1058 
different hypersomnolence disorders, 2. to better understand the precise underlying 1059 
neurobiological of such conditions (i.e. other than narcolepsy type 1),  and finally 3. to 1060 
improve the management of these patients. A registry to validate and optimize our suggested 1061 
approach already exists in Europe within the European Narcolepsy Network (EU-NN) and 1062 
could be extended to a global registry. In addition, studies to further validate the proposed 1063 
diagnostic tools in a prospective setting should be initiated in several sleep labs around the 1064 
world in the next few years. We also call for an international task force to formulate 1065 
guidelines for the proper application of our suggested approach, The topics to be at least 1066 
included: 1067 
 - how to define, assess and treat chronic sleep deprivation in a practicable way 1068 
- what is the best and still feasible way to objectify ENS 1069 
For a better understanding of hypersomnolence disorders in general we must initiate studies to 1070 
get insight in: 1071 
- what determines an individual’s sleep need and can we find biological markers to measure 1072 
this need 1073 
- what is the relation between hypersomnolence and depression and how does it relate to the 1074 
more studied close association between insomnia and depression 1075 
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- what is the exact inter-relation between sleepiness, fatigue and disorders of attention 1076 
We are hopeful that further discussion will lead to a more consistent, widely accepted and 1077 
workable future classification of central disorders of hypersomnolence. We also argue it will 1078 
guide and prioritise our research agenda. Finally, we expect that more detailed attention to the 1079 
multidimensional aspects of hypersomnolence complaints will facilitate and optimise clinical 1080 
care tailored to individual patients. 1081 
 1082 
Conclusion 1083 
We suggest the creation of a new consistent, complaint driven, hierarchical classification for 1084 
central disorders of hypersomnolence; containing levels of certainty, and giving diagnostic 1085 
tests, particularly the MSLT, a weighting based on its specificity and sensitivity in the 1086 
diagnostic context.  1087 
We propose and define three diagnostic categories (with levels of certainty): 1088 
1. “Narcolepsy” 1089 
2. “Idiopathic hypersomnia” 1090 
3. “Idiopathic excessive sleepiness” 1091 
Except for narcolepsy, the diagnoses can only be made after excluding sleep apnea, sleep 1092 
deprivation and circadian disorders as primary causes for hypersomnolence. 1093 
 1094 
 1095 
 1096 
 1097 
 1098 
 1099 
 1100 
 1101 
 1102 
 1103 
 1104 
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 1105 
 1106 
 1107 
 1108 
 1109 
 1110 
 1111 
 1112 
Practice Points 1113 
1. “Hypersomnolence” is the overarching name for the presence of EDS and/or ENS. 1114 
2. EDS and ENS are multidimensional and qualitatively different complaints. 1115 
3. There are large gaps in our understanding of the precise underlying neurobiological 1116 
cause(s) of hypersomnolence and its associated disorders except for narcolepsy type 1. 1117 
Moreover, the impact of lifestyle factors is often poorly characterised or appreciated.  1118 
4.  Sleep deprivation, obstructive sleep apnea and circadian disorders need to be initially 1119 
excluded as primary causes of hypersomnolence before considering a central disorder of 1120 
hypersomnolence as cause of the complaint of excessive daytime sleepiness (except for 1121 
narcolepsy with cataplexy / narcolepsy type 1). 1122 
5. For a reliable diagnosis of narcolepsy type 1, clear and detailed criteria for the presence of 1123 
typical cataplexy are required. 1124 
6. The structure of a classification of sleep disorders, including the chapter on central 1125 
disorders of hypersomnolence, must be complaint driven and not a mixture of complaint 1126 
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driven diagnoses and diagnoses solely based on results of ancillary investigations (i.e. AHI, 1127 
MSLT results).  1128 
7.  We propose and define three diagnostic categories with different levels of certainty and 1129 
subtypes: 1/ “Narcolepsy”; 2/ “Idiopathic hypersomnia”, and 3/ “Idiopathic excessive 1130 
sleepiness”. 1131 
  1132 
 1133 
 1134 
Research Agenda 1135 
We need to: 1136 
1. Understand what determines an individual’s sleep need and identify biological markers for 1137 
it, as for disorders characterised by EDS and ENS. 1138 
2. Develop and validate a guideline to identify and treat chronic sleep deprivation as cause of 1139 
excessive daytime sleepiness. 1140 
3. Better understand how disorders of hypersomnolence progress / develop over years. 1141 
4. Bridge the current gap between disorders of attention and disorders of hypersomnolence. 1142 
5. Better define and understand the proposed association between depression and 1143 
hypersomnolence.  1144 
6. Better understand the inter-relation between sleepiness and fatigue. 1145 
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 1147 
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